Mirpurkhas district in Sindh is emerging as a new hotspot for human immunodeficiency virus (HIV) cases among children, with 150 new cases reported in 2024, according to official statistics, Geo News reported.
In an extraordinary medical achievement, doctors in the Department of Hematology & Stem Cell Transplantation at the Army Hospital R&R have successfully conducted a life-saving Bone Marrow Transplant (commonly known as BMT) for a child diagnosed with a rare primary immunodeficiency di
A recent study published in the Journal of Clinical Immunology has provided light on the particular alterations causing a rare and fatal ailment called 'RAD50 deficiency/Nijmegen breakage syndrome-like disorder'.
Researchers have shed light on the specific variations responsible for an uncommon and deadly condition known as 'RAD50 deficiency/Nijmegen breakage syndrome-like disorder' in a study published recently in the Journal of Clinical Immunology.
Although, after an argument, the health worker allowed the transgender to donate blood, this incident still raises various questions about why a transgender is stopped from donating blood.
Researchers at the University of Colorado Anschutz Medical Campus have helped confirm the dose, safety, and efficacy of a drug formulation designed to treat children infected with the human immunodeficiency virus (HIV).
Researchers at the University of Colorado Anschutz Medical Campus have contributed to the confirmation of the dose, safety, and efficacy of a medication formulation intended to treat children infected with the human immunodeficiency virus (HIV).
Dolutegravir is one of the most potent antiviral drugs now being used in clinical practise to treat HIV. Scientists from the Salk Institute and the National Institutes of Health have discovered the molecular routes through which the human immunodeficiency virus (HIV) develops resistance to i
Researchers from the Salk Institute and the National Institutes of Health have identified the molecular pathways by which the human immunodeficiency virus (HIV) develops resistance to dolutegravir, one of the most potent antiviral medications now being used in clinical use to treat HIV.
Researchers from the Salk Institute and the National Institutes of Health have identified the molecular pathways by which the human immunodeficiency virus (HIV) develops resistance to dolutegravir, one of the most potent antiviral medications now being used in clinical use to treat HIV.
The human immunodeficiency virus type 1 (HIV) inserts a copy of its DNA into human immune cells as a component of its life cycle. HIV latency is the term used to describe the long-lasting inert, latent condition that some of these newly infected immune cells might enter.